ARCHIVES

Seer Places Survival Now at Least At 45 Percent, Could Be As High As 50 Percent For 1973-79 Patients

This article is from The Cancer Letter archive.

Vol. 07 No. 49 | December 4, 1981

Download PDF Visit The Full Archive

Related Articles

Avastin doubles progression-free survival in metastatic disease.

May 27, 2005

Budge Act Includes Language On Coverage Of Oral Cancer Drugs

August 13, 1993

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

July 26, 2013

Clinical Education Program Phase Out Opposed By NCAB Committee

February 14, 1986

DRG Executives Names By DeVita as Director Of DEA; Other Sections Reportedly Made, Not Yet Approved

July 31, 1981

DCT Board Says RDOG Concept Too Expensive; Discusses Grant Funding

July 24, 1992